Efficacy and Safety of Fluvastatin, a New HMG CoA Reductase Inhibitor, in Elderly Hypercholesterolaemic Women
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in Drugs
- Vol. 47 (2) , 59-63
- https://doi.org/10.2165/00003495-199400472-00011
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cardiovascular Health and Disease in WomenNew England Journal of Medicine, 1993
- A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.1993
- Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.1993
- Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal VolunteersThe Journal of Clinical Pharmacology, 1992
- HMG-CoA Reductase Inhibitor Use in the AgedDrugs & Aging, 1992
- Should the elderly be screened for hypercholesterolemia?Archives of internal medicine (1960), 1991
- Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humansAtherosclerosis, 1991
- The epidemiology of cardiovascular disease in older personsAging Clinical and Experimental Research, 1991
- Cholesterol in the Prediction of Atherosclerotic DiseaseAnnals of Internal Medicine, 1979
- Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative UltracentrifugeClinical Chemistry, 1972